|
|
| Product Name: | MMP-2/MMP-9 Inhibitor I | | Synonyms: | Collagenase Type IV 72 kDa;Gelatinase, 72 kDa;Collagenase Type IV 72 kD;72 Kd Gelatinase 72 Kd Type IV collagenase Gelatinase A;Matrix Metalloproteinase-2 human
;PROENZYME MMP-2;PROGELATINASE A;MMP-1 PROENZYME | | CAS: | 193807-58-8 | | MF: | C21H19NO4S | | MW: | 381.44 | | EINECS: | 232-582-9 | | Product Categories: | | | Mol File: | 193807-58-8.mol |  |
| | MMP-2/MMP-9 Inhibitor I Chemical Properties |
| Melting point | 146-147 °C | | Boiling point | 595.9±60.0 °C(Predicted) | | density | 1.297±0.06 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | ≤25mM in DMSO | | pka | 3.26±0.10(Predicted) | | form | powder | | color | light brown | | biological source | human | | Water Solubility | water: soluble | | Specific Activity | ≥600mU/mg protein | | CAS DataBase Reference | 193807-58-8 |
| | MMP-2/MMP-9 Inhibitor I Usage And Synthesis |
| Uses | Matrix metalloproteinase-2 (MMP2) human has been used:
- As a standard in zymography to measure gelatinolytic activity of MMP2.
- In enzymatic method for dissociation of brain tissue to single cells.
| | General Description | Matrix metalloproteinase-2 (MMP-2) also known as gelatinase or type IV collagenase is a 72kDa protein. MMP-2 is a member of matrix metalloproteinase (MMP) family of enzymes. Basic structure of MMP2 contains signal peptide domain that targets the enzyme for secretion, the pro-peptide domain, which is removed when the enzyme is activated and the catalytic site containing gelatin-binding domain. | | Biological Activity | mmp-2/mmp-9 inhibitor i is a potent inhibitor of matrix metalloproteinase-2 (mmp-2) and mmp-9.matrix metalloproteinase (mmp), a typical metalloproteinase, requires zinc ion at its active sites. as many as 18 kinds of mmp have been identified and cloned and are collectively called the mmp family. | | Biochem/physiol Actions | Matrix Metalloproteinase-2 (MMP-2) cleaves gelatin, type IV, V, VII, X, and XI collagens, fibronectin, elastin, laminin, proteoglycans and a range of non extracellular matrix (ECM ) components. MMP-2 cleaves native type I collagen to N-terminal and C-terminal fragments identical to those generated by interstitial collagenases. MMP2 and MMP9 play an essential role in matrix degradation and they are implicated in the maintenance of neovascularization. In mice, deletion or inhibition of MMP2 protects against myocardial rupture. | | in vitro | mmp-2/mmp-9 inhibitor i was identified as a potent inhibitor of matrix metalloproteinase-2 (mmp-2) and mmp-9 with ic50 values of 310 and 240 nm, respectively. mmp-2/mmp-9 inhibitor i acted by binding zinc at the active site of these mmps. mmp-2/mmp-9 inhibitor i was found to be able to block mmp-2/mmp-9-dependent invasion in cell culture model [1]. | | in vivo | both hydroxamic acid and carboxylic acid analogs of mmp-2/mmp-9 inhibitor i were evaluated for their inhibitory activities in animal cancer models. results showed that lung colonization of lewis lung carcinoma cells was suppressed by these inhibitors significantly. in addition, antitumor activity was also observed in the human lung cancer model. ma44 cells growed as a solid tumor on the peritoneum after being implanted ip, and mice bearing ma44 eventually died within 3 to 4 weeks. daily oral administration of compound 5l led to prolonged survival of ma44-bearing mice [1]. | | IC 50 | 310 and 240 nm for mmp-2 and mmp-9, respectively | | Description | MMP2 Human Recombinant produced in E.coli is a single, non-glycosylated polypeptide chain containing 576 amino acids (110-660a.a) and having a molecular mass of 64.7kDa. MMP2 is fused to a 25 amino acid His-tag at N-terminus & purified by proprietary chromatographic techniques. | | Source | Escherichia Coli | | Background | Matrix metalloproteinase-2 (MMP-2) is involved in endometrial menstrual breakdown, regulation of vascularization and the inflammatory response. MMP-2 contains a number of distinct domains: a prodomain that is cleaved upon activation; a catalytic domain containing the zinc binding site; a fibronectin like domain believed to have a role in substrate targeting; and a carboxyl terminal (hemopexin like) domain containing 2 N-linked glycosylation. The MMP-2 can degrade an extensive array of substrates including type IV, V, VII and X collagens as well as gelatin type I. In addition, MMP-2 interacts with THBS2, TIMP2, Thrombospondin 1, CCL7 and TIMP4. MMP-2 autocatalytic cleavage in the C-terminal generates the anti-angiogenic peptide, PEX. This process seems to be made possible by binding integrinv/beta3. Defects in the MMP-2 are the cause of Torg-Winchester syndrome (TWS), aka multicentric osteolysis nodulosis and arthropathy (MONA). | | references | [1] tamura, y. ,watamane, f.,nakatani, t., et al. highly selective and orally active inhibitors of type iv collagenase (mmp-9 and mmp-2): n-sulfonylamino acid derivatives. j. med. chem. 41(4), 640-649 (1998). |
| | MMP-2/MMP-9 Inhibitor I Preparation Products And Raw materials |
|